Artrya Ltd (ASX: AYA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Artrya Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.73 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
78.65 million
Earnings per share
-0.222
Dividend per share
N/A
Year To Date Return
-50.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Artrya Ltd (ASX: AYA)
Latest News
IPOs
New artificial intelligence ASX share rockets 13% on debut
Technology Shares
Move over Appen: A new artificial intelligence stock to list on the ASX
Frequently Asked Questions
-
No, Artrya has not yet paid dividends to shareholders.
-
The company, founded in 2019 in Perth, listed on the ASX on 26 November 2021.
AYA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Artrya Ltd
Artrya Ltd (ASX: AYA) is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease. Artrya’s Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.
The Perth-based company says the technology will revolutionise the speed and accuracy of coronary artery disease diagnosis. The Artrya Ltd share price has steadily declined since the company listed on the ASX in November 2021.
AYA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 08 Dec 2023 | $0.20 | $0.03 | 17.14% | 126,216 | $0.18 | $0.20 | $0.18 |
| 05 Dec 2023 | $0.18 | $-0.01 | -5.56% | 50,000 | $0.19 | $0.19 | $0.18 |
| 04 Dec 2023 | $0.18 | $-0.02 | -10.00% | 22,430 | $0.18 | $0.18 | $0.18 |
| 01 Dec 2023 | $0.20 | $0.02 | 11.11% | 80,000 | $0.20 | $0.20 | $0.20 |
| 28 Nov 2023 | $0.18 | $0.00 | 0.00% | 50,135 | $0.18 | $0.18 | $0.18 |
| 27 Nov 2023 | $0.18 | $0.00 | 0.00% | 79,538 | $0.19 | $0.19 | $0.18 |
| 24 Nov 2023 | $0.18 | $-0.02 | -10.26% | 141,276 | $0.20 | $0.20 | $0.18 |
| 23 Nov 2023 | $0.20 | $0.01 | 5.26% | 84,438 | $0.20 | $0.21 | $0.19 |
| 22 Nov 2023 | $0.19 | $-0.02 | -9.76% | 111,958 | $0.21 | $0.21 | $0.18 |
| 21 Nov 2023 | $0.21 | $0.00 | 0.00% | 183,513 | $0.22 | $0.22 | $0.21 |
| 20 Nov 2023 | $0.20 | $-0.01 | -4.76% | 522,431 | $0.23 | $0.25 | $0.20 |
| 17 Nov 2023 | $0.21 | $0.01 | 4.88% | 33,543 | $0.22 | $0.22 | $0.21 |
| 14 Nov 2023 | $0.21 | $-0.03 | -12.77% | 300 | $0.24 | $0.24 | $0.21 |
| 10 Nov 2023 | $0.24 | $0.05 | 26.32% | 1,914 | $0.24 | $0.24 | $0.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 May 2023 | Catherine (Kate) Hill | Buy | 100,000 | $25,700 |
On-market trade.
|
| 31 Mar 2023 | Bernard (Bernie) Ridgeway | Buy | 300,000 | $95,935 |
On-market trade.
|
| 06 Mar 2023 | Catherine (Kate) Hill | Buy | 10,312 | $3,486 |
On-market trade.
|
| 01 Mar 2023 | Catherine (Kate) Hill | Buy | 89,688 | $31,095 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Bernard (Bernie) William Ridgeway | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
Mr Ridgeway brings a wealth of corporate experience to Artrya, including 37 years in private and ASX listed companies, spending most of that time in the role of Managing Director. During that time, Imdex's revenue grew from approximately $20m per annum in Australia to more than of $270m per annum, generated from sales from over 100 countries. In that period, the market capitalisation of Imdex grew from below $10m to over $600m, and now exceeds $750m. His vision is for Artrya to become the global standard in non-invasive AI and machine learning to diagnose and treat coronary artery disease.
|
| Dr Jacque Sokolov | Non-Executive Director | Aug 2022 |
Dr Jacque Sokolov joined the Artrya Board as a Non-Executive Director on 1 August 2022. Dr Sokolov has a experience across all aspects of the US healthcare industry, in particular healthcare delivery, biotechnology, and regulatory clearance. He was appointed Artrya Clinical Advisory Board Chair in January 2022 and Chairman and President of Artrya USA Inc. in March 2022. Dr. Sokolov is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US diversified healthcare management, development, and financial services company. His company has worked with more than 100 healthcare organisations across multiple US healthcare sectors to develop physician-driven, value-focused solutions in rapidly evolving markets
|
| Ms Catherine (Kate) Hill | Non-Executive Director | Feb 2023 |
Ms Hill has over 20 years' experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately-owned clients. She has worked in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment. She held a variety of leadership and executive roles in Deloitte and served for a period on the Board of Partners of the Australian firm.
|
| Mr Kevin R Hart | Company Secretary | Oct 2022 |
-
|
| Kevin R Hart | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| No top 20 shareholder's information disclosed | 0 | 0.00% |
